BioVie to Host March 4 Webinar on NE3107 and BIV201 Progress
BioVie will host a live webinar on March 4, 2026 at 4:15 p.m. ET to discuss bezisterim (NE3107) and orphan drug BIV201. NE3107 has shown improved cognition, motor function and reduced neuroinflammation in Alzheimer’s and Parkinson’s studies, and BIV201 is advancing toward a Phase 3 cirrhosis and ascites trial.
1. Webinar Details
BioVie will host a live investor webinar on March 4, 2026 at 4:15 p.m. ET, featuring CEO Cuong Do. A live Q&A session will follow the presentation, and investors can pre-submit questions via email.
2. NE3107 Clinical Signals
Bezisterim (NE3107) is a first-in-class orally available small molecule targeting inflammation and insulin resistance, key drivers of Alzheimer’s and Parkinson’s disease. Clinical studies have shown encouraging signals of improved cognition, motor function and reduced neuroinflammation in these patient populations.
3. BIV201 Orphan Drug Progress
BIV201, BioVie’s orphan drug candidate for cirrhosis and ascites, has received FDA Orphan and Fast Track designations. The company plans a Phase 3 trial to assess BIV201’s efficacy in reducing decompensation events in patients with advanced liver cirrhosis.
4. Outlook and Market Potential
Multiple clinical programs are advancing toward late-stage development with strong safety data. BioVie highlights multi-billion-dollar market opportunities and potential partnership catalysts as it approaches pivotal milestones across its neuroscience and liver disease portfolios.